Johnson & Johnson reports Phase 2b Rybrevant Faspro lung cancer data

Johnson & Johnson presented early results on 14 September 2026 from its Phase 2b COPERNICUS study at the World Conference on Lung Cancer in Seoul, South Korea. The trial evaluated subcutaneous Rybrevant Faspro combined with Lazcluze alongside prophylactic strategies in 214 previously untreated U.S. patients with EGFR-mutated advanced non-small cell lung cancer.

At a median follow-up of 8.3 months, rash occurred in 25 percent of patients, while administration-related reactions and venous thromboembolism each occurred in 3 percent. Eight percent of patients discontinued treatment due to adverse events, with 1 percent discontinuing due to rash and 1 percent due to blood clots, while no patients discontinued because of administration-related reactions. Most adverse events were Grade 1 or 2, with no new safety signals observed.

These adverse event figures compare favorably to earlier intravenous results from the Phase 3 MARIPOSA trial, where first-line patients experienced rates of 55 percent for rash, 55 percent for administration-related reactions, and 23 percent for venous thromboembolism during the initial four months. In MARIPOSA, the combination also showed an overall survival benefit compared with osimertinib, with a hazard ratio of 0.75.

The reported COPERNICUS patient group had a median age of 67 years, with 22 percent aged 75 or older. Demographic breakdown showed 27 percent Asian, 10 percent African American, and 10 percent Hispanic or Latino participants, toward an eventual overall enrollment target of 300 patients.